MAP2K7 and melanoma: Simultaneous deletion of NF1 and SUZ12 is presented in 24% melanoma and 14% GBM cases and dual inhibition of MEK and BET induces the genetic context-specific replication fork stalling and DNA damage, highlighting the potential therapeutic benefit of the combinatory treatment.